JIMD Reports (Sep 2021)

Energy metabolism during exercise in patients with β‐enolase deficiency (GSDXIII)

  • Astrid Emilie Buch,
  • Olimpia Musumeci,
  • Ralph Wigley,
  • Mads Peter Godtfeldt Stemmerik,
  • Anne‐Sofie Vibæk Eisum,
  • Karen Lindhardt Madsen,
  • Nicolai Preisler,
  • David Hilton‐Jones,
  • Ros Quinlivan,
  • Antonio Toscano,
  • John Vissing

DOI
https://doi.org/10.1002/jmd2.12232
Journal volume & issue
Vol. 61, no. 1
pp. 60 – 66

Abstract

Read online

Abstract Aim To investigate the in vivo skeletal muscle metabolism in patients with β‐enolase deficiency (GSDXIII) during exercise, and the effect of glucose infusion. Methods Three patients with GSDXIII and 10 healthy controls performed a nonischemic handgrip test as well as an incremental cycle ergometer test measuring maximal oxidative consumption (VO2max) and a 1‐hour submaximal cycle test at an intensity of 65% to 75% of VO2max. The patients repeated the submaximal exercise after 2 days, where they received a 10% iv‐glucose supplementation. Results Patients had lower VO2max than healthy controls, and two of three patients had to stop prematurely during the intended 1‐hour submaximal exercise test. During nonischemic forearm test, all patients were able to produce lactate in normal amounts. Glucose infusion had no effect on patients' exercise capacity. Conclusions Patients with GSDXIII experience exercise intolerance and episodes of myoglobinuria, even to the point of needing renal dialysis, but still retain an almost normal anaerobic metabolic response to submaximal intensity exercise. In accordance with this, glucose supplementation did not improve exercise capacity. The findings show that GSDXIII, although causing episodic rhabdomyolysis, is one of the mildest metabolic myopathies affecting glycolysis.

Keywords